Published online before print January 5, 2004, doi: 10.1161/01.ATV.0000115637.48689.77
© 2004 American Heart Association, Inc.
Vascular Biology |
Increased Endothelial Tetrahydrobiopterin Synthesis by Targeted Transgenic GTP-Cyclohydrolase I Overexpression Reduces Endothelial Dysfunction and Atherosclerosis in ApoE-Knockout Mice
From the Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Correspondence to Prof K. M. Channon, Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK. E-mail keith.channon{at}cardiov.ox.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Increased production of reactive oxygen species and loss of endothelial nitric oxide (NO) bioactivity are key features of vascular disease states such as atherosclerosis. Tetrahydrobiopterin (BH4) is a required cofactor for NO synthesis by endothelial nitric oxide synthase (eNOS); pharmacologic studies suggest that reduced BH4 availability may be an important mediator of endothelial dysfunction in atherosclerosis. We aimed to investigate the importance of endothelial BH4 availability in atherosclerosis using a transgenic mouse model with endothelial-targeted overexpression of the rate-limiting enzyme in BH4 synthesis, GTP-cyclohydrolase I (GTPCH).
Methods and Results— Transgenic mice were crossed into an ApoE knockout (ApoE-KO) background and fed a high-fat diet for 16 weeks. Compared with ApoE-KO controls, transgenic mice (ApoE-KO/GCH-Tg) had higher aortic BH4 levels, reduced endothelial superoxide production and eNOS uncoupling, increased cGMP levels, and preserved NO-mediated endothelium dependent vasorelaxations. Furthermore, aortic root atherosclerotic plaque was significantly reduced in ApoE-KO/GCH-Tg mice compared with ApoE-KO controls.
Conclusions— These findings indicate that BH4 availability is a critical determinant of eNOS regulation in atherosclerosis and is a rational therapeutic target to restore NO-mediated endothelial function and reduce disease progression.
Key Words: nitric oxide synthase • endothelium • atherosclerosis • hypercholesterolemia
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Nitric oxide (NO) produced in the endothelium by endothelial nitric oxide synthase (eNOS) is a key mediator of vascular homeostasis. NO bioavailability is reduced early in vascular disease states such as hypercholesterolemia and atherosclerosis because of reduced NO synthesis and increased NO consumption by reactive oxygen species.1 A critical determinant of eNOS activity is the availability of the NOS cofactor tetrahydrobiopterin (BH4). When BH4 levels are inadequate, the enzymatic reduction of molecular oxygen by eNOS is no longer coupled to L-arginine oxidation, resulting in generation of superoxide rather than NO, thus contributing to vascular oxidative stress and endothelial dysfunction. BH4 bioavailability in the vasculature appears to be regulated at the level of biosynthesis by the rate-limiting enzyme GTP-cyclohydrolase I (GTPCH) and by oxidative degradation of BH4 to dihydrobiopterin (BH2) that is inactive for eNOS cofactor function.
Several pharmacologic studies suggest a possible role for BH4 availability in regulating NO-mediated endothelial function. Acute administration of BH4 improves some features of endothelial dysfunction in smokers,2 and in patients with type
See page 397
II diabetes,3 hypercholesterolemia,4,5 or coronary atherosclerosis.6 In hypercholesterolemic ApoE-knockout (ApoE-KO) mice, endothelium-dependent vascular relaxations are impaired, NO synthesis is reduced, and vascular superoxide production is increased.7,8 However, endothelial dysfunction in ApoE-KO mice can be reduced by incubation of vessels in the BH4 precursor sepiapterin.8 Transgenic overexpression of eNOS in ApoE-KO mice surprisingly leads to enhanced vascular superoxide production, reduced NO bioavailability, and accelerated atherosclerosis.9 BH4 levels are reduced in the aortas of these mice compared with wild-type controls, but dietary BH4 supplementation with sapropterin reduces superoxide production and increases NO synthesis. These results suggest that increased eNOS protein alone is insufficient to maintain NO synthesis in hypercholesterolemia, and that adequate BH4 levels are essential to prevent eNOS uncoupling in endothelial dysfunction states. However, the effects of topical or systemic pharmacologic BH4 supplementation in these studies may be mediated in part by nonspecific antioxidant effects of acute high-dose BH4, which can increase apparent NO bioavailability by nonspecific ROS scavenging. Furthermore, the long-term effects of endothelial BH4 augmentation in the pathogenesis of vascular disease states are uncertain. Indeed, the effects of pharmacologic supplementation with BH4 or other biopterin analogues on NO bioactivity are unpredictable in vascular disease states in which oxidative stress is increased10,11 and in which oxidation of BH4 to BH2 by reactive oxygen species such as peroxynitrite may be an important mechanism underlying BH4 loss.8,12
Accordingly, we sought to investigate the importance of BH4 availability in experimental atherosclerosis using a novel transgenic mouse model with endothelial-targeted overexpression of GTPCH, the rate-limiting enzyme in BH4 synthesis. In this model, endothelial cell BH4 levels are specifically increased 3- to 4-fold, without elevation of plasma BH4 levels.13 We crossed this transgenic mouse line into an ApoE-KO background to investigate the effects of sustained targeted increases in endothelial BH4 synthesis on NO-mediated endothelial function and on progression of atherosclerosis.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals
All studies involving laboratory animals were conducted in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986. Mice were housed in temperature-controlled cages (20°C to 22°C) with a 12-hour light-dark cycle and were given free access to water and formulated diets. GTPCH transgenic (GCH-Tg) mice, in which human GTPCH transgene overexpression is targeted to the vascular endothelium under the control of the mouse Tie-2 promoter, were generated in a C57Bl/6 background as previously described.13 GCH-Tg mice have increased endothelial GTPCH mRNA expression and protein production, resulting in a 3- to 4-fold augmentation of vascular BH4 levels. These mice were cross-bred through two generations with ApoE-KO mice,14 also in a C57BL/6 background (purchased from Jackson Laboratory, Bar Harbor, ME), to produce ApoE-KO/GCH-Tg heterozygote breeders. Breeders were mated with pure ApoE-KO mice to produce equal numbers of GCH-Tg (ApoE-KO/GCH-Tg) and nontransgenic (ApoE-KO) littermates in an ApoE-KO background, which were used in all experiments. Mice were weaned at age 3 weeks onto a high-fat pelleted "western" diet (no. 100244; Dyets, Bethlehem, PA). The composition of this diet in g/kg was: casein 195, DL-methionine 3, cornstarch 150, sucrose 341, cellulose 50, anhydrous milk fat 210, salt mix 35, vitamin mix 10, calcium carbonate 4, cholesterol 1.5, and ethoxyquin 0.04. After 16 weeks of feeding on this high-fat diet, mice were euthanized and organs were used in experiments described.
Measurement of Plasma Lipid Concentration
Biochemical analyses of plasma lipids were performed on heparinized blood plasma using a Cobas Mira Plus automated analyzer (Roche, Switzerland).
Measurement of Biopterins
Measurements of total biopterins (BH4, BH2, and biopterin) and biopterins excluding BH4 (BH2 and biopterin) were performed by HPLC analysis with fluorescent detection after differential iodine oxidation of tissue extracts in either acidic or alkaline conditions, respectively, as previously described.13,15 BH4 concentration, expressed as pmol/mg protein, was calculated by subtracting BH2+biopterin from total biopterins.
Oxidative Fluorescent Microtopography
Superoxide production in tissue sections of mouse aorta was detected using the fluorescent probe dihydroethidium as previously described.16 Fresh segments of upper descending thoracic aorta were frozen in OCT compound. Cryosections (30 µm) were incubated with Krebs HEPES buffer (in mmol/L: NaCl 99; KCl 4.7; MgSO4 1.2; KH2PO4 1.0; CaCl2 1.9; NaHCO3 25; glucose 11.1, NaHEPES 20) for 30 minutes at 37°C with or without 1 mmol/L L-NAME (Sigma), then for another 5 minutes in a light-protected chamber at 37°C with 2 µmol/L dihydroethidium (DHE; Molecular Probes). Some sections were also incubated with 500 U/mL polyethylene glycol-conjugated superoxide dismutase (PEG-SOD) (Sigma) to demonstrate specificity of ethidium fluorescence for superoxide. Images were obtained using a Bio-Rad MRC-1024 laser scanning confocal microscope equipped with a krypton/argon laser using identical acquisition settings. For quantification of endothelial cell ethidium fluorescence from high-power (x60) images, fluorescence (intensity x area) was measured only on the luminal side of the internal elastic lamina using Image-Pro Plus software (MediaCybernetics, Silver Spring, MD). For each vessel, mean fluorescence was calculated from 4 separate high-power fields taken in each quadrant of the vessel to produce n=1.
Measurement of Cyclic GMP Levels
Cyclic GMP levels in aortas were measured as previously described.17,18 Briefly, aortas were opened and preincubated for 15 minutes in oxygenated Krebs-HEPES solution with 0.1 mmol/L isobutylmethylxanthine (IBMX) (Sigma) at 37°C, then stimulated with 1 µmol/L acetylcholine for 3 minutes. Vessels were immediately snap-frozen in liquid nitrogen and homogenized in ice-cold 5% trichloroacetic acid containing 0.5 mmol/L IBMX. Cyclic GMP levels were measured in vessel extracts by enzyme immunoassay (Cayman Chemical Co), expressed as picomoles cGMP per milligram of TCA-precipitable protein solubilized with 1 mol/L sodium hydroxide.
Isometric Tension Vasomotor Studies
Aortic vasomotor function was analyzed using isometric tension studies. Two rings, each 2 mm in length, were cut from the midpoint of each thoracic aorta and mounted in organ bath chambers (Multi-Myograph 610 mol/L, Danish Myo Technology, Aarhus, Denmark) containing 5 mL Krebs-Henseleit Buffer (KHB, in mmol/L: NaCl 120; KCl 4.7; MgSO4 1.2; KH2PO4 1.2; CaCl2 2.5; NaHCO3 25; glucose 5.5) at 37°C, and gassed with 95% O2/5% CO2. All experiments were performed in the presence of 10 µmol/L indomethacin to inhibit vascular prostaglandin synthesis. Serial responses to 60 mmol/L KCl, followed by cumulative half-log concentrations of phenylephrine (PE) (1x10-9 to 1x10-5 mol/L) and acetylcholine (Ach) (1x10-9 to 1x10-5 mol/L) after preconstriction with PE (3x10-6 mol/L), and the NO donor sodium nitroprusside (SNP) (1x10-10 to 1x10-6 mol/L) were determined as previously described.13
Histologic Analysis of Aortic Root Plaque
Immediately after being euthanized, mice were perfusion-fixed with 4% paraformaldehyde in phosphate-buffered saline via the left ventricle. Hearts were dissected and immersed in fixative for a further 24 hours. Each heart was transected at the level of the atria, dehydrated, paraffin-embedded, and serially sectioned (5 µm) onto glass slides. Three aortic root sections per mouse (spaced approximately 80 µm apart, encompassing the lower, middle, and upper parts of the aortic valve cusps) were rehydrated and stained with combined Elastic (Sigma, Dorset, UK) (to stain elastic laminae black) and Masson’s trichrome (VWR, Dorset, UK) (to stain collagen green and cardiac myocytes red). Digital images of the aortic root sections were analyzed using Image Pro Plus (Media Cybernetics). Total lesion area in the aortic root (mean of 3 sections per mouse) was measured blind to the identity of each section and expressed in mm2.
Statistical Analysis
For isometric tension studies, mean responses of two rings from each animal were combined to produce n=1. Dose response curves from groups were compared using a general linear model ANOVA test for repeated measures (SPSS v10.0). For other comparisons, one-way ANOVA or t tests were used. P<0.05 was considered significant. Data are expressed as means and SEM.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Plasma Lipid Profiles in Mice Fed a High-Fat Diet
Both ApoE-KO and ApoE-KO/GCH-Tg mice had markedly increased plasma total cholesterol and triglyceride levels when fed a high-fat diet for 16 weeks, but there were no significant differences between the two groups (Table).
|
Effect of GTPCH Overexpression on Aortic Biopterin Levels
We first determined whether increased GTPCH expression within the endothelium of ApoE-KO/GCH-Tg mice would lead to increased BH4 levels by measuring biopterins in homogenates of snap-frozen aorta. Total biopterin levels were approximately 2-fold higher and BH4 levels were 3-fold higher in ApoE-KO/GCH-Tg compared with ApoE-KO aorta (Figure 1A) as a result of GTPCH over-expression. In ApoE-KO/GCH-Tg mice, BH4 levels represented 71% of total biopterins, compared with 38% in ApoE-KO mice, suggesting increased oxidative degradation of BH4 in ApoE-KO mice (Figure 1B). This finding suggests that increased endothelial BH4 levels in ApoE-KO/GCH-Tg mice are associated with reduced aortic oxidative stress in atherosclerosis.
|
Effect of Increased BH4 Levels on Endothelial
Superoxide Production and eNOS Coupling
To investigate the source of oxidative stress in mouse aorta, we measured superoxide production using dihydroethidium oxidative fluorescent microtopography. Ethidium fluorescence was observed throughout all layers of the vessel wall that could be inhibited by preincubation with PEG-SOD (data not shown). We next focused on the contribution of eNOS to vascular superoxide production in endothelial cells by measuring ethidium fluorescence specifically on the luminal side of the internal elastic lamina. Endothelial ethidium fluorescence in ApoE-KO mice was increased 2-fold compared with ApoE-KO/GCH-Tg mice, indicating increased superoxide production within endothelial cells (Figure 2). Incubation of aortic sections with 1 mmol/L L-NAME to inhibit eNOS decreased endothelial ethidium fluorescence in ApoE-KO aortas, suggesting that in these mice eNOS uncoupling resulted in a net generation of superoxide. In contrast, L-NAME incubation increased endothelial ethidium fluorescence in ApoE-KO/GCH-Tg aortas, indicating maintenance of eNOS coupling, with a net production of NO rather than superoxide.
|
Cyclic GMP Levels in Aortas
To evaluate whether maintenance of eNOS coupling in ApoE-KO/GCH-Tg mice increased NO bioavailability, we measured aortic cGMP levels in ApoE-KO/GCH-Tg and ApoE-KO mice. cGMP levels were increased 2-fold in ApoE-KO/GCH-Tg mice compared with ApoE-KO mice (Figure 3). These results indicate that maintenance of endothelial BH4 levels by GTPCH overexpression in ApoE-KO mice augments NO bioavailability and signaling in the vascular wall.
|
Effect of Increased BH4 Levels on Endothelial Function
We next determined the functional relationships between aortic BH4 levels and eNOS-dependent vasomotor function in ApoE-KO and ApoE-KO/GCH-Tg mice. Isometric tension studies revealed no difference in vascular contractions to phenylephrine among the two groups of mice (Figure 4A). However, endothelium-dependent relaxations to the receptor-mediated eNOS agonist acetylcholine (ACh) were significantly impaired in ApoE-KO mice compared with relaxations in ApoE-KO/GCH-Tg mice (Figure 4B). Indeed, endothelium-dependent relaxations in ApoE-KO/GCH-Tg mice were not significantly impaired in comparison with control C57Bl/6J mice fed a high-fat diet (data not shown). Endothelium independent relaxations to the NO donor sodium nitroprusside were identical in both groups, demonstrating no difference in vascular smooth muscle responses to NO (Figure 4C). These observations indicate that increased endothelial BH4 levels preserve NO-mediated endothelial function in atherosclerosis.
|
Development of Aortic Root Plaque
To investigate the effect of preserved endothelial function in ApoE-KO/GCH-Tg mice on the progression of atherosclerosis, we quantified aortic root plaque area after 16 weeks of high-fat feeding. Mean aortic root plaque area after 16 weeks of high-fat diet was 28% lower in ApoE-KO/GCH-Tg mice compared with ApoE-KO mice (Figure 5). This result indicates that the development of atherosclerosis in ApoE-KO mice is directly related to NO-mediated endothelial function and can be significantly reduced by a targeted increase in endothelial BH4 bioavailability.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this study we describe a new mouse model in which endothelial-targeted overexpression of GTPCH leads to a persistent increase in endothelial BH4 levels in an ApoE-KO background. We used this model to investigate the role of BH4 in hypercholesterolemic endothelial dysfunction and report the following major findings. First, endothelial-specific overexpression of GTPCH is sufficient to increase vascular BH4 levels in atherosclerosis. Second, uncoupled eNOS contributes to endothelial superoxide production in ApoE-KO aortas, but eNOS coupling is preserved by increased vascular BH4 levels in ApoE-KO/GCH-Tg aortas. Third, increased BH4 synthesis in ApoE-KO mice is associated with increased NO bioavailability, as demonstrated by increased aortic cGMP levels and preserved endothelial-dependent vascular relaxations. Fourth, preserved endothelial function by GTPCH overexpression in ApoE-KO mice reduces atherosclerosis progression.
Previous studies have reported increased superoxide production, at least partly derived from uncoupled eNOS, in the aorta of ApoE-KO mice,7,8 diabetic rats,19 and hyperlipidemic rabbits.20 In agreement with these studies, we also found that uncoupled eNOS contributes to superoxide production specifically within endothelial cells and is associated with increased oxidation of BH4, forming BH2 and biopterin. The mechanisms underlying increased oxidative stress in vascular disease states include enzyme systems such as the NADPH oxidases, in addition to eNOS uncoupling in the endothelium. Reducing NADPH oxidase-mediated ROS production has salutary effects on atherosclerotic progression in ApoE-KO mice21 and on NO-mediated vascular function and eNOS coupling in DOCA-salt hypertension,22 suggesting that NADPH oxidase-mediated ROS can initiate eNOS uncoupling through BH4 oxidation. However, initial eNOS uncoupling may progressively increase oxidative degradation of BH4, resulting in a positive feed-forward spiral of reduced NO production and increasing eNOS-mediated superoxide generation. In support of this model, some studies have suggested that agents such as ascorbate23,24 and folate,25 known to improve endothelial dysfunction, may act through stabilization or regeneration of BH4. We now add further direct evidence suggesting a central role for BH4-mediated eNOS uncoupling in the progressive endothelial dysfunction of atherosclerosis. By specifically augmenting vascular BH4 levels in ApoE-KO mice, using endothelial-targeted transgenic overexpression of GTPCH, we found that eNOS coupling was maintained, leading to reduced endothelial superoxide production and increased NO bioavailability. Our observations suggest that maintenance of BH4 levels in atherosclerosis is alone sufficient to rescue the deficit in eNOS function, despite the overall increase in vascular oxidative stress.8 However, it should be noted that direct evidence of eNOS uncoupling in vascular disease has not been demonstrated in vivo, because of the technical limitations involved in the measurement of vascular superoxide production.26 In addition, our experiments cannot exclude a possible effect of increased endothelial BH4 levels on the activity of the inducible NOS isoform in other cells of the vascular wall, which likely contributes to vascular pathophysiology in ApoE-KO mice.24,27,28
Improving eNOS coupling by constitutive augmentation of endothelial BH4 levels in the ApoE-KO mouse model of atherosclerosis also allowed us to investigate the long-term effects of this intervention on NO-mediated endothelial function and on atherosclerotic plaque progression in vivo. Reduced endothelial superoxide production and increased NO bioactivity, as evidenced by cGMP levels, significantly improved vascular relaxations to acetylcholine in GCH-Tg atherosclerotic mice. Indeed, in these animals, vasorelaxations were maintained at levels indistinguishable from levels in control C57Bl/6J mice fed a high-fat diet. Importantly, these findings demonstrate that targeted preservation of NO-mediated endothelial function is sufficient to reduce plaque progression in atherosclerosis, adding further weight to the concept that endothelial dysfunction is indeed a direct contributor in the pathogenesis of atherosclerosis, rather than an indirect marker of disease progression.
Our study suggests that BH4 is a rational therapeutic target to correct endothelial dysfunction in atherosclerosis. Strategies to persistently improve BH4 availability may be effective in restoring NO-mediated endothelial function and limiting vascular disease progression in several conditions, such as atherosclerosis,8,9 diabetes,13 and hypertension.22 Paradoxically, targeted eNOS overexpression alone as a strategy to restore or increase vascular NO bioactivity in atherosclerosis neither restores NO-mediated endothelial function nor reduces atherosclerosis.9 Rather, eNOS overexpression in atherosclerosis has detrimental effects because of superoxide generated by eNOS uncoupling, which is corrected by high-dose BH4 supplementation.9 However, high pharmacological doses of sepiapterin or BH4 (often >100-fold in excess of physiological concentrations) may increase NO bioactivity via nonspecific antioxidant effects. The present study addresses this potential limitation by using GTPCH overexpression in transgenic mice to only modestly increase endothelial BH4 synthesis and vascular BH4 levels. Taken together with previous studies, our observations suggest that BH4 availability, rather than total eNOS enzymatic activity, is a more critical regulator of NO production in atherosclerosis and has direct effects on NO-mediated endothelial function and on atherosclerotic progression.
The mechanisms underlying reduced BH4 availability in vascular diseases remain incompletely understood and may involve several pathways. BH4 levels in inflammatory cells are regulated principally by transcriptional upregulation of GTPCH in response to cytokine stimulation. Although similar observations have been described in cultured endothelial cells,29,30 there is little evidence for major changes in endothelial GTPCH expression and BH4 synthesis in vivo in the setting of vascular diseases. For example, GTPCH expression does not appear upregulated in the vasculature in a mouse model of diabetes,13 and there are conflicting comparisons of aortic BH4 levels in ApoE-KO mice compared with controls.9,24 Reduced endothelial BH4 levels in vascular diseases could be caused by inhibition of GTPCH enzymatic activity secondary to either phosphorylation or feedback inhibition through GTPCH feedback regulatory protein.31 However, previous data suggest that oxidative degradation of BH4 by peroxynitrite (forming BH2 and biopterin via the nonprotonated BH3 radical32) is a more likely explanation for reduced BH4 levels in atherosclerosis8 and in other vascular disease states.13,22 Indeed, in the present study we observed that the ratio of BH4 to oxidized biopterins was reduced in aortas of ApoE-KO mice compared with ApoE-KO/GCH-Tg mice, adding further support to this conclusion. We found, in addition, that maintenance of endothelial BH4 levels appears sufficient to limit BH4 oxidation by preservation of eNOS coupling. Thus, eNOS-dependent superoxide production mediated by BH4 insufficiency further reduces BH4 availability. Although reduced biosynthesis of BH4 may not be the principal mechanism of BH4 loss in vascular disease, the GCH-Tg mouse model clearly shows that increasing endothelial BH4 biosynthesis is nevertheless effective in restoring BH4 availability. Strategies aimed at increasing BH4 biosynthesis,33 reducing BH4 oxidation,22,24,25 or enhancing BH4 regeneration32 may be equally valid as therapeutic approaches in vascular disease states.
|
Acknowledgments |
|---|
Acknowledgments
This work was supported by the British Heart Foundation. N. J. A. is a Wellcome Trust Cardiovascular Research Initiative Training Fellow.
|
Footnotes |
|---|
Tetrahydrobiopterin (BH4), synthesized by GTP-cyclohydrolase-1 (GTPCH), is a required cofactor for NO synthesis by eNOS. Endothelial-targeted GTPCH-transgenic mice crossed into an ApoE knockout background (ApoE-KO/GCH-Tg) demonstrated higher aortic BH4 levels, reduced endothelial superoxide production, increased NO bioavailability, and reduced atherosclerosis compared with ApoE-KO controls. These findings indicate that BH4 availability is a critical determinant of eNOS regulation in atherosclerosis.
Received September 26, 2003; accepted December 19, 2003.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000; 87: 840–844.
2. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000; 86: E36–E41.
3. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia. 2000; 43: 1435–1438.[CrossRef][Medline] [Order article via Infotrieve]
4. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997; 99: 41–46.[Medline] [Order article via Infotrieve]
5. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart. 2002; 87: 264–269.
6. Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, Meier B, Luscher TF. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol. 2000; 35: 173–178.[CrossRef][Medline] [Order article via Infotrieve]
7. d’Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC, Katusic ZS. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 1017–1022.
8. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG. Endothelial regulation of vasomotion in ApoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001; 103: 1282–1288.
9. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K-i, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest. 2002; 110: 331–340.[CrossRef][Medline] [Order article via Infotrieve]
10. Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol. 2002; 22: 1655–1661.
11. Tarpey MM. Sepiapterin treatment in atherosclerosis. Arterioscler Thromb Vasc Biol. 2002; 22: 1519–1521.
12. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun. 1999; 263: 681–684.[CrossRef][Medline] [Order article via Infotrieve]
13. Alp NJ, Mussa S, Khoo J, Guzik TJ, Cai S, Jefferson A, Rockett KA, Channon KM. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I over-expression. J Clin Invest. 2003; 119: 725–735.
14. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A. 1992; 89: 4471–4475.
15. Cai S, Alp NJ, Mc Donald D, Canevari L, Heales S, Channon KM. GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerization. Cardiovasc Res. 2002; 55: 838–849.
16. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002; 105: 1656–1662.
17. Leopold JA, Zhang YY, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol. 2003; 23: 411–417.
18. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, Yokoyama M. Hypotension and reduced nitric oxide- elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest. 1998; 102: 2061–2071.[Medline] [Order article via Infotrieve]
19. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001; 88: E14–E22.
20. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A, Walter U, Skatchkov M, Meinertz T, Munzel T. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric Oxide/cGMP signaling and endothelial dysfunction. Circ Res. 2000; 87: 999–1005.
21. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest. 2001; 108: 1513–1522.[CrossRef][Medline] [Order article via Infotrieve]
22. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003; 111: 1201–1209.[CrossRef][Medline] [Order article via Infotrieve]
23. Huang A, Vita JA, Venema RC, Keaney J. Ascorbic acid enhances endothelial nitric oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem. 2000.
24. d’Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res. 2003; 92: 88–95.
25. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, Rabelink TJ. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 2000; 86: 1129–1134.
26. Munzel T, Afanas’ev IB, Kleschyov AL, Harrison DG. Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol. 2002; 22: 1761–1768.
27. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation. 2001; 103: 3099–3104.
28. Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock J, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow CP, Chao YS, Rader DJ, Wright SD, Pure E. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. 2000; 165: 3430–3435.
29. Hattori Y, Nakanishi N, Kasai K, Shimoda SI. GTP cyclohydrolase I mRNA induction and tetrahydrobiopterin synthesis in human endothelial cells. Biochim Biophys Acta. 1997; 1358: 61–66.[Medline] [Order article via Infotrieve]
30. Linscheid P, Schaffner A, Blau N, Schoedon G. Regulation of 6-pyruvoyltetrahydropterin synthase activity and messenger RNA abundance in human vascular endothelial cells. Circulation. 1998; 98: 1703–1706.
31. Gesierich A, Niroomand F, Tiefenbacher CP. Role of human GTP cyclohydrolase I and its regulatory protein in tetrahydrobiopterin metabolism. Basic Res Cardiol. 2003; 98: 69–75.[CrossRef][Medline] [Order article via Infotrieve]
32. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem. 2003; 278: 22546–22554.
33. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2003; 23: 176–182.
This article has been cited by other articles:
 |
|
 |
|
  M. J. Crabtree, A. L. Tatham, A. B. Hale, N. J. Alp, and K. M. Channon Critical Role for Tetrahydrobiopterin Recycling by Dihydrofolate Reductase in Regulation of Endothelial Nitric-oxide Synthase Coupling: RELATIVE IMPORTANCE OF THE DE NOVO BIOPTERIN SYNTHESIS VERSUS SALVAGE PATHWAYS J. Biol. Chem., October 9, 2009; 284(41): 28128 - 28136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gao, Y.-F. Pung, J. Zhang, P. Chen, T. Wang, M. Li, M. Meza, L. Toro, and H. Cai Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H331 - H339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Ceylan-Isik, K. K. Guo, E. C. Carlson, J. R. Privratsky, S.-J. Liao, L. Cai, A. F. Chen, and J. Ren Metallothionein Abrogates GTP Cyclohydrolase I Inhibition-Induced Cardiac Contractile and Morphological Defects: Role of Mitochondrial Biogenesis Hypertension, June 1, 2009; 53(6): 1023 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Peterson, L. V. d'Uscio, S. Cao, X.-L. Wang, and Z. S. Katusic Guanosine Triphosphate Cyclohydrolase I Expression and Enzymatic Activity Are Present in Caveolae of Endothelial Cells Hypertension, February 1, 2009; 53(2): 189 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Crabtree, A. L. Tatham, Y. Al-Wakeel, N. Warrick, A. B. Hale, S. Cai, K. M. Channon, and N. J. Alp Quantitative Regulation of Intracellular Endothelial Nitric-oxide Synthase (eNOS) Coupling by Both Tetrahydrobiopterin-eNOS Stoichiometry and Biopterin Redox Status: INSIGHTS FROM CELLS WITH TET-REGULATED GTP CYCLOHYDROLASE I EXPRESSION J. Biol. Chem., January 9, 2009; 284(2): 1136 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kim, M. Pham, E. Maloney, N. O. Rizzo, G. J. Morton, B. E. Wisse, E. A. Kirk, A. Chait, and M. W. Schwartz Vascular Inflammation, Insulin Resistance, and Reduced Nitric Oxide Production Precede the Onset of Peripheral Insulin Resistance Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1982 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Ali, C. A. Bursill, G. Douglas, E. McNeill, M. Papaspyridonos, A. L. Tatham, J. K. Bendall, A. M. Akhtar, N. J. Alp, D. R. Greaves, et al. CCR2-Mediated Antiinflammatory Effects of Endothelial Tetrahydrobiopterin Inhibit Vascular Injury-Induced Accelerated Atherosclerosis Circulation, September 30, 2008; 118(14_suppl_1): S71 - S77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, J. Xu, P. Song, Y. Wu, J. Zhang, H. Chul Choi, and M.-H. Zou Acute Inhibition of Guanosine Triphosphate Cyclohydrolase 1 Uncouples Endothelial Nitric Oxide Synthase and Elevates Blood Pressure Hypertension, September 1, 2008; 52(3): 484 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antoniades, C. Shirodaria, T. Van Assche, C. Cunnington, I. Tegeder, J. Lotsch, T. J. Guzik, P. Leeson, J. Diesch, D. Tousoulis, et al. GCH1 Haplotype Determines Vascular and Plasma Biopterin Availability in Coronary Artery Disease: Effects on Vascular Superoxide Production and Endothelial Function J. Am. Coll. Cardiol., July 8, 2008; 52(2): 158 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sasaki, T. Yamashita, T. Takaya, M. Shinohara, R. Shiraki, M. Takeda, N. Emoto, A. Fukatsu, T. Hayashi, K. Ikemoto, et al. Augmentation of Vascular Remodeling by Uncoupled Endothelial Nitric Oxide Synthase in a Mouse Model of Diabetes Mellitus Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1068 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Moens, E. Takimoto, C. G. Tocchetti, K. Chakir, D. Bedja, G. Cormaci, E. A. Ketner, M. Majmudar, K. Gabrielson, M. K. Halushka, et al. Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin: Efficacy of Recoupling Nitric Oxide Synthase as a Therapeutic Strategy Circulation, May 20, 2008; 117(20): 2626 - 2636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Wohlfart, H. Xu, A. Endlich, A. Habermeier, E. I. Closs, T. Hubschle, C. Mang, H. Strobel, T. Suzuki, H. Kleinert, et al. Antiatherosclerotic Effects of Small-Molecular-Weight Compounds Enhancing Endothelial Nitric-Oxide Synthase (eNOS) Expression and Preventing eNOS Uncoupling J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 370 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ryoo, G. Gupta, A. Benjo, H. K. Lim, A. Camara, G. Sikka, H. K. Lim, J. Sohi, L. Santhanam, K. Soucy, et al. Endothelial Arginase II: A Novel Target for the Treatment of Atherosclerosis Circ. Res., April 25, 2008; 102(8): 923 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Moens, H. C. Champion, M. J. Claeys, B. Tavazzi, P. M. Kaminski, M. S. Wolin, D. J. Borgonjon, L. Van Nassauw, A. Haile, M. Zviman, et al. High-Dose Folic Acid Pretreatment Blunts Cardiac Dysfunction During Ischemia Coupled to Maintenance of High-Energy Phosphates and Reduces Postreperfusion Injury Circulation, April 8, 2008; 117(14): 1810 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Du, Y.-Y. Guan, N. J. Alp, K. M. Channon, and A. F. Chen Endothelium-Specific GTP Cyclohydrolase I Overexpression Attenuates Blood Pressure Progression in Salt-Sensitive Low-Renin Hypertension Circulation, February 26, 2008; 117(8): 1045 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sukhanov, Y. Higashi, S.-Y. Shai, C. Vaughn, J. Mohler, Y. Li, Y.-H. Song, J. Titterington, and P. Delafontaine IGF-1 Reduces Inflammatory Responses, Suppresses Oxidative Stress, and Decreases Atherosclerosis Progression in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2684 - 2690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Whitsett, M. J. Picklo Sr, and J. Vasquez-Vivar 4-Hydroxy-2-Nonenal Increases Superoxide Anion Radical in Endothelial Cells via Stimulated GTP Cyclohydrolase Proteasomal Degradation Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2340 - 2347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. De Bono and K. M. Channon Endothelial Cell Tetrahydrobiopterin: Going With the Flow Circ. Res., October 12, 2007; 101(8): 752 - 754. [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, Y. Wu, P. Song, M. Zhang, S. Wang, and M.-H. Zou Proteasome-Dependent Degradation of Guanosine 5'-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus Circulation, August 21, 2007; 116(8): 944 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fukai Endothelial GTPCH in eNOS Uncoupling and Atherosclerosis Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1493 - 1495. [Full Text] [PDF]
|
|
|
|
|
|
T. Takaya, K.-i. Hirata, T. Yamashita, M. Shinohara, N. Sasaki, N. Inoue, T. Yada, M. Goto, A. Fukatsu, T. Hayashi, et al. A Specific Role for eNOS-Derived Reactive Oxygen Species in Atherosclerosis Progression Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1632 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hattori, S. Hattori, X. Wang, H. Satoh, N. Nakanishi, and K. Kasai Oral Administration of Tetrahydrobiopterin Slows the Progression of Atherosclerosis in Apolipoprotein E-Knockout Mice Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 865 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Thum, D. Fraccarollo, M. Schultheiss, S. Froese, P. Galuppo, J. D. Widder, D. Tsikas, G. Ertl, and J. Bauersachs Endothelial Nitric Oxide Synthase Uncoupling Impairs Endothelial Progenitor Cell Mobilization and Function in Diabetes Diabetes, March 1, 2007; 56(3): 666 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Adlam, J. K. Bendall, J. P. De Bono, N. J. Alp, J. Khoo, T. Nicoli, M. Yokoyama, S. Kawashima, and K. M. Channon Cardiovascular Control: Relationships between nitric oxide-mediated endothelial function, eNOS coupling and blood pressure revealed by eNOS-GTP cyclohydrolase 1 double transgenic mice Exp Physiol, January 1, 2007; 92(1): 119 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Moens and D. A. Kass Tetrahydrobiopterin and Cardiovascular Disease Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2439 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. d'Uscio and Z. S. Katusic Increased vascular biosynthesis of tetrahydrobiopterin in apolipoprotein E-deficient mice Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2466 - H2471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang and X.-F. Ming Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res., March 1, 2006; 4(1): 53 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Bevers, B. Braam, J. A. Post, A. J. van Zonneveld, T. J. Rabelink, H. A. Koomans, M. C. Verhaar, and J. A. Joles Tetrahydrobiopterin, but Not L-Arginine, Decreases NO Synthase Uncoupling in Cells Expressing High Levels of Endothelial NO Synthase Hypertension, January 1, 2006; 47(1): 87 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Eskurza, L. A Myerburgh, Z. D Kahn, and D. R Seals Tetrahydrobiopterin augments endothelium-dependent dilatation in sedentary but not in habitually exercising older adults J. Physiol., November 1, 2005; 568(3): 1057 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Bendall, N. J. Alp, N. Warrick, S. Cai, D. Adlam, K. Rockett, M. Yokoyama, S. Kawashima, and K. M. Channon Stoichiometric Relationships Between Endothelial Tetrahydrobiopterin, Endothelial NO Synthase (eNOS) Activity, and eNOS Coupling in Vivo: Insights From Transgenic Mice With Endothelial-Targeted GTP Cyclohydrolase 1 and eNOS Overexpression Circ. Res., October 28, 2005; 97(9): 864 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cai, J. Khoo, and K. M. Channon Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells Cardiovasc Res, March 1, 2005; 65(4): 823 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Li and A. M Shah Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1014 - R1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. S. Katusic and L. V. d'Uscio Tetrahydrobiopterin: Mediator of Endothelial Protection Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 397 - 398. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||